BiotechTube

AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleukin-2

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed or Refractory Hodgkin Lymphoma

Conditions

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma

Trial Timeline

Oct 10, 2023 → Jun 13, 2025

NCT ID
NCT05883449

About AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleukin-2

AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleukin-2 is a phase 2 stage product being developed by Artiva Biotherapeutics for Relapsed or Refractory Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05883449. Target conditions include Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05883449Phase 2Terminated

Competing Products

20 competing products in Relapsed or Refractory Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
agenT-797MiNK TherapeuticsPhase 1
25
VIP152 + BTKiVincerx PharmaPhase 1
25
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
77
AC220Daiichi SankyoPhase 1
33
Valemetostat TosylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
AGS67EAstellas PharmaPhase 1
33
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
41
LenvatinibEisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
Eribulin mesylateEisaiPhase 2
52
ME-401Kyowa KirinPhase 1
33
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6Kyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
ONO-4685Ono PharmaceuticalPhase 1
33
ONO-4685Ono PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77

Other Products from Artiva Biotherapeutics

Allogeneic NK CellsPhase 2
44
AB-201 + Cyclophosphamide + FludarabinePhase 1/2
33
AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Fludarabine + BendamustinePhase 1/2
33
GCC2005 + Cyclophosphamide + FludarabinePhase 1
25
AB-101 + Cyclophosphamide + Fludarabine + Rituximab + ObinutuzumabPhase 1
25